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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2309The New York State Cardiac RegistriesEdward L. Hannan, Kimberly Cozzens, Spencer B. King III, Gary Walford, Nirav R. Shah
In 1988, the New York State Health Commissioner was confronted with hospital-level data
demonstrating large inter hospital variations in short-term mortality and complications for
cardiac surgery. This led to the development of clinical registries for cardiac surgery in 1989
and percutaneous coronary interventions in 1992 to determine if this variation was due to
patients’ pre-surgical severity of illness or hospitals’ quality of care. This paper relates the
history of this initiative and its effects, both real and conjectured. The real effects include
decreases in risk-adjusted mortality and cessation of cardiac surgery in New York by low-
volume and high-mortality surgeons. There is less evidence for referrals to out-of-state
providers or avoidance of cardiac surgery/angioplasty for high-risk patients.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY2317Clinical Outcomes After TAVR Using VARC DefinitionsPhilippe Généreux, Stuart J. Head, Nicolas M. Van Mieghem, Susheel Kodali, Ajay J. Kirtane, Ke Xu,
Craig Smith, Patrick W. Serruys, A. Pieter Kappetein, Martin B. Leon
The recently published Valve Academic Research Consortium (VARC) definitions have
helped to add uniformity for reporting outcomes after transcatheter aortic valve replacement
(TAVR). Généreux and colleagues performed a weighted meta-analysis to determine rates of
major outcomes after TAVR using VARC definitions. A total of 16 studies reporting at least
1 outcome using VARC definitions were included. The pooled estimate rate of outcomes
according to VARC’s definitions: device success: 92%; all-cause 30-day mortality: 7.8%; major
vascular complication: 12%; major stroke: 3.2%. VARC definitions have already been used by
the TAVR clinical research community, establishing a new standard for reporting clinical
outcomes and facilitating comparisons between different devices or techniques.(continued on page A-26)




EINTERVENTIONAL CARDIOLOGY2327No Evidence That Drug-Eluting Balloon Beneficial for STEMI PatientsAnouar Belkacemi, Pierfrancesco Agostoni, Hendrik Nathoe, Michiel Voskuil, ChunLai Shao, Eric Van Belle,
Thierry Wildbergh, Luigi Politi, Pieter A. Doevendans, Giuseppe M. Sangiorgi, Pieter R. Stella
There is controversy about whether bare-metal stents (BMS) or drug-eluting stents (DES)
should be used for ST-segment elevation myocardial infarction (STEMI). The DEB-AMI
trial tested the hypothesis that a drug-eluting balloon (DEB) plus BMS could provide an
attractive alternative potentially reducing the risk of restenosis while limiting the long-term
hazards related to late-acquired stent malapposition. In this randomized, 3-arm study,
STEMI patients were randomly assigned to: BMS; DEB plus BMS; or DES after successful
thrombus aspiration. Late luminal loss, binary restenosis, and MACE rates were similar for
BMS and DEB-BMS and lower for DES. In STEMI patients, DEB followed by BMS
implantation failed to show angiographic superiority to BMS only.ANTIPLATELET THERAPY
2338Recovery of Platelet Function Following Discontinuation of
Prasugrel or Clopidogrel Maintenance DosingMatthew J. Price, James S. Walder, Brian A. Baker, Darell E. Heiselman, Joseph A. Jakubowski,
Douglas K. Logan, Kenneth J. Winters, Wei Li, Dominick J. Angiolillo
Price and colleagues studied the lingering effect on platelet inhibition after discontinuing
clopidogrel or prasugrel. Aspirin-treated subjects were randomly assigned to either prasugrel
10 mg or clopidogrel 75 mg daily for 7 days. Platelet reactivity was measured prior to study
drug and for up to 12 days during washout. The primary endpoint of the trial was the return
to baseline platelet function defined as platelet reactivity within 60 PRU prior to study drug
administration. After prasugrel, 75% of subjects returned to baseline reactivity by washout
day 7 compared with day 5 after clopidogrel. Recovery time was dependent upon the level of
platelet reactivity prior to study drug exposure and the initial degree of platelet inhibition after
study drug discontinuation, but not upon treatment assignment.CARDIOMETABOLIC DISORDERS2344PCSK9 Antibody Lowers LDL LevelsJames M. McKenney, Michael J. Koren, Dean J. Kereiakes, Corinne Hanotin, Anne-Catherine Ferrand,
Evan A. Stein
McKenney and colleagues tested the hypothesis that an antibody targeting serum proprotein
convertase subtilisin kexin 9 (PCSK9) would lower low-density lipoprotein cholesterol
(LDL-C) levels by lowering the rate at which LDL receptors (LDLR) are broken down,
thus increasing the clearance of Apo-B–containing particles. This trial randomized 183
patients with LDL-C 100 mg/dl on stable-dose atorvastatin to SAR236553 at varying does
nd timing intervals or placebo. SAR236553 demonstrated a clear dose–response relationship
ith up to 72% LDL-C reduction at 12 weeks. SAR236553 was generally well tolerated but
subject experienced a serious adverse event of leucocytoclastic vasculitis. When added to
torvastatin, PCSK9 inhibition with SAR236553 further reduces LDL-C by up to 72%.ditorial Comment: Robert Vogel, page 2354
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Børge G. Nordestgaard
Benn and colleagues used longitudinal data from 80,000 Danish citizens to study the link
between genetic polymorphisms linked to elevated nonfasting glucose and cardiac risk.
Individuals were genotyped for variants in GCK, G6PC2, ADCY5, DGKB, and ADRA2A.
The risk of ischemic heart disease (IHD) and myocardial infarction (MI) increased stepwise
with increasing nonfasting glucose levels with a hazard ratio for IHD in individuals with
nonfasting glucose levels 11 mmol/l (198 mg/dl) versus 5 mmol/l (90 mg/dl) of 6.9
after adjusting for age and gender and 2.3 adjusted multifactorially. The number of glucose
increasing alleles was also associated with increasing nonfasting glucose levels and with
increased risk of IHD. Further analyses suggested that the polymorphisms were causally
related to the risk, with nonfasting glucose being the intermediary.CARDIAC RESYNCHRONIZATION THERAPY2366Predictors of Super-Response to CRTJonathan C. Hsu, Scott D. Solomon, Mikhail Bourgoun, Scott McNitt, Ilan Goldenberg, Helmut Klein,
Arthur J. Moss, Elyse Foster, on behalf of the MADIT-CRT Executive Committee
Hsu and colleagues investigated predictors of left ventricular ejection fraction (LVEF)
super-response to cardiac resynchronization therapy with defibrillator (CRT-D) in mildly
symptomatic (NYHA functional class I to II) heart failure (HF) patients. Super-response was
defined by the top quartile of LVEF change at 12 months. Super-responders experienced an
LVEF increase 14.5% (mean LVEF increase 17.5%). Six predictors were associated with
LVEF super-response to CRT-D therapy: female, no prior myocardial infarction, QRS
duration 150 ms, left bundle branch block, body mass index 30 kg/m2, and smaller
baseline left atrial volume index. The cumulative probability of HF or all-cause death at 2
years of was 4% in super-responders, 11% in responders, and 26% in hypo-responders.Editorial Comment: Kenneth Ellenbogen, page 2374VIEWPOINT2378Cardiac Surgeon Report Cards and the Ethical Responsibilities of CardiologistsDavid L. Brown, Stephen Clarke, Justin Oakley
Individual, risk-adjusted cardiac surgery mortality data is currently available for over 25% of
the U.S. population as well as for Great Britain and Ireland. Although cardiologists are the
primary source of referral, surveys and market share analyses suggest they are not using this
information to refer to cardiac surgeons with the lowest mortality rates. Brown and colleagues
review the ethical principles that should obligate cardiologists to discuss and use outcomes
data prior to referring their patients. An accompanying commentary by Shahian and
Normand disagrees about the utility of using this data to discriminate superior from average
surgeons and that criteria other than 30-day mortality may also be important to patients.Commentary: David M. Shahian, Sharon-Lise T. Normand, page 2383
